Table 1: Characteristics of HDAC inhibitors in clinical trials.

ChemistryCompoundsHDAC TargetsClinical trialsRef

HydroxymatesSAHA (vorinostat)Classes I, II, and IVPhase III*[6]
PXD101 (belinostat)Classes I, and IIa, HDAC6Phase II[7]
Trichostatin AClasses I and IIToxic[8]
LAQ824 (dacinostat)Classes I and IIPhase I[9]
PCI24781Classes I and IIbPhase I[10]
LBH589 (panobinostat)Classes I and IIaPhase II[11]

Cyclic tetrapeptidesFK228 (romidepsin)HDAC1, 2, 4, 6Phase II[12]

BenzamidesMGCD0103 (mocetinostat)HDAC1, 2, 3, 11Phase II[13]
MS275 (entinostat)HDAC1, 2, 3, 9Phase II[14]

Short-chain fatty acidsValproic acidClasses I and IIaPhase II[15]
ButyrateClasses I and IIaPhase II[16]

*Approved (cutaneous T-cell lymphoma).